ArticleCardiovascular diabetology2026
Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999-2018.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study.Cardiovascular diabetology · 2026Observational
- Atherogenic index of plasma and risk of hypertensive disorders of pregnancy in women with gestational diabetes mellitus: a two-center cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe atherogenic index of plasma (AIP) serves as a crucial indicator for assessing atherosclerotic risk. It reflects the degree of dyslipidaemia and cardiovascular disease (CVD) risk. The cardiometabolic index (CMI) provides a comprehensive evaluation of obesity-related metabolic risk, acting as a key biomarker for predicting multiple cardiometabolic diseases. The relationship between AIP and CMI in patients with non-alcoholic fatty liver disease (NAFLD) and mortality or CVD risk remains unclear.
methodsThis study included 5792 adult (≥ 18 years) NAFLD patients from the US National Health and Nutrition Examination Survey (NHANES, 1999-2018). Weighted logistic regression and Cox proportional hazards models were employed to investigate the association between AIP, CMI and all-cause mortality, CVD mortality and CVD risk. Restricted cubic spline (RCS) curves assessed non-linear associations. Subgroup analyses and mediation analyses examined the effect modifiers and mediators. The incremental predictive value of AIP and CMI was evaluated. Sensitivity analyses were conducted to validate the robustness.
resultsDuring follow-up, 721 all-cause deaths (including 241 CVD deaths) and 726 total CVD events were recorded. After adjusting for confounding factors, patients in the highest quartiles of AIP and CMI had a significantly higher risk of specific CVD events. The strongest association was observed for CHF (AIP: OR = 3.157, 95% CI 1.684, 5.922, p < 0.001; CMI: OR = 3.604, 95% CI 1.843, 7.047, p < 0.001), followed by heart attack and CHD. CMI consistently demonstrated a stronger effect than AIP. RCS analysis indicates a non-linear relationship between CMI and CHD, angina pectoris. Subgroup analysis revealed that both AIP and CMI demonstrated high predictive value for all-cause mortality in the 40-60 age cohort. Mediation analysis revealed that Mets, NLR, hypertension and HOMA-IR partially mediated the aforementioned associations. The inclusion of AIP and CMI partially improved the predictive capability of the basic model. Sensitivity analyses validated the robustness of these findings.
conclusionsIn patients with NAFLD, CMI is a stronger predictor of non-fatal CVD than AIP. While both indices show limited value for predicting mortality, CMI holds promise as a practical supplementary tool for clinical risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.